ABOUT US

Castle Biosciences is a leading diagnostics company that provides personalized, clinically actionable information to clinicians and patients to inform treatment decisions and improve health outcomes. The company is focused on transforming the disease management paradigm leveraging advanced technologies for its portfolio of innovative tests for skin cancers, uveal melanoma and Barrett's esophagus. (www.CastleTestInfo.com) TissueCypher   Barrett's Esophagus Assay is the first and only precision medicine test that can predict the future development of esophageal cancer in patients with Barrett's esophagus and is an independent risk predictor from tissue histology and other clinical risk factors. The test is intended for patients with a confirmed diagnosis of Barrett's esophagus graded non-dysplastic, indefinite for dysplasia or low-grade dysplasia, and provides a five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma. (www.tissuecypher.com)